Skip to main content
OpenTrials
Completed

NCT Number: NCT01043250

Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients

In this study, we are going to investigate quantitative and qualitative natures of appetite and eating-behavior changes induced by atypical antipsychotics, i.e., risperidone, olanzapine and aripiprazole, in schizophrenia patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–59 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Samsung Medical Center

Seoul, 135-710, South Korea

About this study

This is an observational study. 2 Self-report questionnaires assessing changes of appetite and eating behaviors after medication are applied to patients who have been receiving one of the three atypical antipsychotics. We are going to compare changes of appetite and eating behaviors after medication between three atypical antipsychotics and investigate the association between changes of appetite and eating behaviors and changes of weight after medication.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients meeting the DSM-IV criteria of schizophrenia, schizophreniform disorder, or schizoaffective disorder
  • Male and female patients aged 19~59
  • Patients receiving monotherapy with one of the three AAPs, i.e., olanzapine, risperidone, and aripiprazole for more than two and less than 24 months
  • Patients who had at least one-week antipsychotics-free periods before starting the above antipsychotics
  • Clinically stable and able to complete the questionnaires
  • Patients who sufficiently understand the objective of the study and sign informed consent form

Exclusion criteria

  • Patients having any medical illness or taking any medicine affecting appetite and body weight
  • Patients with severe and unstable medical, neurological or systemic illnesses
  • Patients having any comorbid psychiatric disorders including substance use disorders and eating disorders.
  • Pregnant or breast-feeding women

Treatment and study plan

Primary outcomes

  1. Changes in appetite and eating behavior Rating Scales: Drug-related eating behavior questionnaire & Korean version of General Food Craving Questionnaire

    Time frame: between 2 and 24months after starting medication

Secondary outcomes

  1. Body mass index (BMI)

    Time frame: between 2 and 24 months after starting medication

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Collaborators

  • Korea Otsuka Pharmaceutical Co., Ltd.
  • Ministry of Health & Welfare, Korea

Registry information

Official study title

Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Jan 6, 2010
Registry last updated
Jul 25, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.